Pharmacokinetics and safety of coformulated bictegravir, emtricitabine, and tenofovir alafenamide in children aged 2 years and older with virologically suppressed HIV: a phase 2/3, open-label, single-arm study
Carina A. Rodriguez, Eva Natukunda, Renate Strehlau, Esme L Venter, Supattra Rungmaitree, Coleen K. Cunningham, Umesh Lalloo, Pope Kosalaraksa, Elizabeth Hellström, Afaaf Liberty, Eric McGrath, Meenu Kaur, Rory Leisegang, Jason T. Hindman, Vinícius Vieira, Kathryn Kersey, Mark F. Cotton, Natella Rakhmanina, Aditya H. Gaur
Topics & Concepts
MedicineEmtricitabineTenofovir alafenamideTenofovirHuman immunodeficiency virus (HIV)PharmacokineticsPhases of clinical researchVirologyOpen labelAntiretroviral therapyDermatologyAdverse effectInternal medicineClinical trialViral loadHIV/AIDS drug development and treatmentHIV-related health complications and treatmentsHIV/AIDS Research and Interventions